Literature DB >> 19343472

A case of "refractory" lupus erythematosus profundus responsive to rituximab [case report].

Adrian McArdle1, Joshua F Baker.   

Abstract

Lupus erythematosus profundus is a rare complication of systemic lupus erythematosus characterized by the presence of deep, tender subcutaneous nodules. A 22-year-old African-American female with extensive lupus profundus resistant to conventional therapies was treated with two infusions of the anti-CD20 monoclonal antibody, rituximab, at a dosage of 1,000 mg each. The patient demonstrated a remarkable clinical response as indicated by the disappearance of the nodules. B-cell depletion therapy with rituximab used alone or in combination with other therapies may be a viable option in patients with lupus profundus refractory to current therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19343472     DOI: 10.1007/s10067-009-1158-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  6 in total

Review 1.  Management of "refractory" skin disease in patients with lupus erythematosus.

Authors:  Jeffrey P Callen
Journal:  Best Pract Res Clin Rheumatol       Date:  2005-10       Impact factor: 4.098

Review 2.  Lupus erythematosus profundus successfully treated with dapsone: review of the literature.

Authors:  Hideyuki Ujiie; Tadamichi Shimizu; Miki Ito; Ken Arita; Hiroshi Shimizu
Journal:  Arch Dermatol       Date:  2006-03

3.  Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy.

Authors:  J Ordi-Ros; F Cortés; E Cucurull; M Mauri; S Buján; M Vilardell
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

Review 4.  Lupus erythematosus panniculitis.

Authors:  M S Peters; W P Su
Journal:  Med Clin North Am       Date:  1989-09       Impact factor: 5.456

Review 5.  Lupus erythematosus panniculitis.

Authors:  Javier Fraga; Amaro García-Díez
Journal:  Dermatol Clin       Date:  2008-10       Impact factor: 3.478

6.  Lupus panniculitis: clinical perspectives from a case series.

Authors:  P B Martens; K G Moder; I Ahmed
Journal:  J Rheumatol       Date:  1999-01       Impact factor: 4.666

  6 in total
  4 in total

1.  Update on management of connective tissue panniculitides.

Authors:  Inbal Braunstein; Victoria P Werth
Journal:  Dermatol Ther       Date:  2012 Mar-Apr       Impact factor: 2.851

Review 2.  Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature.

Authors:  S C Hofmann; M J Leandro; S D Morris; D A Isenberg
Journal:  Lupus       Date:  2013-08       Impact factor: 2.911

3.  Lupus profundus limited to a site of trauma: Case report and review of the literature.

Authors:  María Adriana Castrillón; Dédée F Murrell
Journal:  Int J Womens Dermatol       Date:  2017-05-05

4.  Lupus erythematosus panniculitis resistant to standard treatment, complicated with macrophage activation syndrome.

Authors:  Katarzyna Juczynska; Anna Wozniacka; Elzbieta Waszczykowska; Agnieszka Zebrowska
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.